Longevica
Longevica Therapeutics is a US preclinical biotech that has run the world's largest mouse longevity screen (1,033 compounds, 20,000+ mice) and is building an AI-trained drug discovery platform to develop human and pet healthspan therapeutics, supplements, and licensed IP.
- Company typePrivate
- Founded2009
- HeadquartersPrinceton, United States
- Headcount1–10
- GTM typeB2B and B2C
- OfferingServices
What Longevica does
Longevica Therapeutics is a US preclinical-stage biotech (founded 2009, headquartered in Belmont, California) whose stated mission is to identify mechanisms of human life extension. The company has built what it describes as the world's largest mouse longevity screening program, testing 1,033 compounds across more than 20,000 mice, and reports that 60+ compounds extended lifespan by over 10% and 5 compounds by 16–22%. Its core technology stack centers on a Longevity AI Platform trained on this proprietary dataset, combined with bioinformatics and systems biology methods, aimed at accelerating human longevity drug discovery and identifying candidate compounds for translational development. In November 2021 the company also launched an Open Research Platform providing external scientists with access to its data and screening infrastructure.
The company is pursuing a multi-track commercialization strategy: (1) human healthspan therapeutics and supplements advancing toward IND-enabling trials, (2) pet longevity supplements and therapies, (3) IP licensing and patent monetization around key longevity compounds (including a granted US patent for a life-extending method), and (4) platform access for academic and pharmaceutical partners. GTM motion is primarily enterprise/B2B — direct investor outreach, pitch-deck distribution, and partnership development with pharmaceutical and research-institution counterparts. Longevica has disclosed $15.5M in cumulative funding, most recently a $2.5M round led by Xploration Capital in November 2021, and operates with a small (1–10) employee base supplemented by an advisory bench drawn from Harvard, UC Berkeley, and Rutgers.
Revenue is not publicly disclosed; no commercial therapeutic product is yet on market, and the company characterizes itself as actively fundraising to support advanced R&D and commercial translation. The hybrid B2B/B2C customer strategy — health-conscious consumers, pet owners, pharma licensors, and academic researchers — has not yet translated into named customer relationships or material revenue per the available data.
Longevica firmographics
Firmographics- Name
- Longevica
- Legal name
- Longevica Therapeutics
- Website
- https://longevica.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Longevica Therapeutics is a US preclinical biotech that has run the world's largest mouse longevity screen (1,033 compounds, 20,000+ mice) and is building an AI-trained drug discovery platform to develop human and pet healthspan therapeutics, supplements, and licensed IP.
- Ownership category
- akta.pro rank
Longevica industry classification
Industry- Product category
- Longevity Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro industry
- AI/ML Platforms for Drug Discovery & Experiment OptimizationHealthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)Translational Medicine & BiomarkersMedical Wellness & Longevity (Health Screening, Biohacking, Anti-aging Programs)Travel & Hospitality/Tours, Attractions & Experiences/Wellness & Spa Experiences (Retreats, Thermal Baths, Yoga)
Keywords
Where Longevica is headquartered
LocationHeadquarters
- HQ city
- Princeton
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Longevica business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Science-backed Therapies and Supplements: Developing and commercializing science-backed therapies and supplements for human healthspan extension and pet longevity. Moving into translational research, IND-enabling studies, and supplement safety monitoring.
- Longevity Research Platform Access: Open research platform for studying pharmacological compounds, providing access to data and infrastructure for scientific research, supporting development of consumer-ready products.
- IP Licensing and Patent Monetization: Strong patent portfolio on key longevity compounds with potential for licensing and patent monetization. Recently obtained US patent for life-extending method.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Longevica product offering
Product offeringCore offering
Longevica conducts the world's largest mouse longevity studies and uses the resulting proprietary dataset to train an AI-driven drug discovery platform aimed at accelerating human longevity therapeutics. Building on this research base, the company develops science-backed therapies and supplements for human and pet healthspan, while providing an open research platform for external researchers and IND-enabling translational research services.
Product overview
Longevica is a life science company that has conducted the world's largest mouse longevity studies (testing over 1,033 compounds on 20,000 mice). The company offers an integrated portfolio consisting of an Open Research Platform providing external access to their longevity data and infrastructure, a Longevity AI Platform for AI-driven drug discovery, Human Healthspan & Longevity Therapeutics (science-backed therapies and supplements), Pet Health & Longevity products, and Translational Research & Clinical Development services. The company is moving from foundational research into translational research and clinical development to bring real-world impact to patients, consumers, and their pets.
Differentiator
Problem solved
Functional benefit
Products and services
- Open Research Platform Open research platform providing external access to Longevica's longevity research data and screening infrastructure for studying pharmacological compounds related to aging and life extension.
- Longevity AI Platform AI-driven drug discovery platform trained on the world's largest longevity screening dataset from mouse studies, designed to accelerate the identification and development of human longevity drugs by combining bioinformatics, systems biology, and AI approaches.
- Human Healthspan & Longevity Therapeutics Science-backed therapies and supplements developed to help people live longer, healthier lives by extending human healthspan.
- Pet Health & Longevity Cutting-edge supplements and therapies developed to help pets live longer, healthier, and happier lives.
- Translational Research & Clinical Development IND-enabling studies and supplement safety monitoring services that advance promising longevity compounds from research through clinical development, including nutrivigilance for supplements.
Quantifiable outcome
- 60+ compounds extended lifespan by over 10% in mouse studies
- +3 more outcomes
Companies that use Longevica
Customer profileSegments4 records
Ideal customer profiles5 records
Longevica technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Longevica partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered minor.
- Harvard UniversityminorDr. Adrian Salic, Professor at Harvard, serves as Scientific Advisor, contributing expertise in cell signaling and Hedgehog pathway research that led to development of Click-iT kits.
- UC BerkeleyminorDr. Steven Garan, Director of CRE Aging at UC Berkeley, serves as Chief Scientific and Technology Advisor. Known for inventing AIMS, coining 'Phenomics', and work on caloric restriction effects.
- Rutgers UniversityminorDr. Alexey Ryazanov, Professor at Rutgers, serves as Scientific Advisor with over 20 years of experience in molecular biology and aging mechanisms research.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
Longevica competitors and assessment
Company assessmentDirect peers
- Insilico Medicine: AI-driven drug discovery company using proprietary datasets and generative models to identify novel therapeutics, including in aging/longevity. Directly comparable to Longevica's AI longevity platform thesis and pipeline approach.
- Recursion Pharmaceuticals: AI-enabled drug discovery company generating proprietary biological datasets at scale to power ML-driven target identification and translational pipelines. Comparable technology stack, data-centric moat, and small-molecule development model.
- BioAge Labs: Clinical-stage biotech using AI and human cohort data to identify therapeutics that target aging biology. Comparable discovery thesis combining proprietary datasets with translational drug development in longevity indications.
- Unity Biotechnology: Clinical-stage longevity biotech developing senolytic therapeutics to address age-related diseases. Direct competitor in the aging-pharmaceutical space, with more advanced clinical assets but similar translational risk.
- Elysium Health: Longevity consumer supplements company built on aging-biology research (NAD+, cellular health). Comparable supplement commercialization angle and longevity science positioning, though Elysium is consumer-only without drug discovery.
- Loyal for Dogs: Pet longevity biotech developing FDA-conditional drugs to extend dog lifespan. Direct peer on Longevica's pet longevity product line, with similar regulatory pathway challenges in animal healthspan.
- Life Biosciences: Longevity biotech pursuing multiple partial reprogramming and gene therapy programs to address aging. Operates in the same aging-therapeutics space with comparable platform ambitions and translational stage.
Broad incumbents
- Altos Labs: Well-capitalized (~$3B) longevity biotech pursuing cellular rejuvenation programming. Operates in the same longevity therapeutic space with vastly greater resources and a broader biological reprogramming approach.
- Calico Life Sciences: Alphabet-funded longevity R&D company with deep resources focused on aging biology and therapeutics. Same longevity drug-discovery thesis, but with vastly larger capital base and longer investment horizon.
Emerging players
- Tally Health: Consumer longevity brand offering epigenetic age testing and supplements. Adjacent consumer-facing longevity play that overlaps with Longevica's supplement ambitions but lacks drug-discovery operations.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Longevica social profiles
Digital presenceLongevica financial estimates
Financial estimateRevenue estimate
Valuation estimate
Longevica leadership team
Management profileNumber of profiles
Profiles14 records
Longevica funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Longevica M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Longevica
What does Longevica do?
Longevica conducts the world's largest mouse longevity studies and uses the resulting proprietary dataset to train an AI-driven drug discovery platform aimed at accelerating human longevity therapeutics. Building on this research base, the company develops science-backed therapies and supplements for human and pet healthspan, while providing an open research platform for external researchers and IND-enabling translational research services.
Is Longevica a public or private company?
Longevica is a private company. It is classified as venture growth investor backed and is currently operating.
When was Longevica founded?
Longevica was founded in 2009. It employs 1 to 10 people.
Where is Longevica based?
Longevica is headquartered in Princeton, United States, in the North America region.
How does Longevica make money?
Three revenue lines are on record. Science-backed Therapies and Supplements are the primary driver. The others are longevity Research Platform Access and IP Licensing and Patent Monetization.
Who are Longevica's main competitors?
Direct peers on record are Insilico Medicine, Recursion Pharmaceuticals, BioAge Labs, Unity Biotechnology, Elysium Health, Loyal for Dogs and Life Biosciences. Broad incumbents are Altos Labs and Calico Life Sciences. Tally Health is listed as an emerging player.
Does Longevica have an API?
No public API is recorded for Longevica.
What industry is Longevica in?
Longevica's product category is Longevity Therapeutics. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAK, In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy). Its NAICS code is 541714 and its SIC code is 2834.